@article{Nkumama:2024:10.1016/j.immuni.2024.05.001,
author = {Nkumama, IN and Ogwang, R and Odera, D and Musasia, F and Mwai, K and Nyamako, L and Murungi, L and Tuju, J and Fürle, K and Rosenkranz, M and Kimathi, R and Njuguna, P and Hamaluba, M and Kapulu, MC and Frank, R and CHMI-SIKA, study team and Osier, FHA},
doi = {10.1016/j.immuni.2024.05.001},
journal = {Immunity},
pages = {1215--1224.e6},
title = {Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.},
url = {http://dx.doi.org/10.1016/j.immuni.2024.05.001},
volume = {57},
year = {2024}
}

Download

TY  - JOUR
AB  - Malaria is a life-threatening disease of global health importance, particularly in sub-Saharan Africa. The growth inhibition assay (GIA) is routinely used to evaluate, prioritize, and quantify the efficacy of malaria blood-stage vaccine candidates but does not reliably predict either naturally acquired or vaccine-induced protection. Controlled human malaria challenge studies in semi-immune volunteers provide an unparalleled opportunity to robustly identify mechanistic correlates of protection. We leveraged this platform to undertake a head-to-head comparison of seven functional antibody assays that are relevant to immunity against the erythrocytic merozoite stage of Plasmodium falciparum. Fc-mediated effector functions were strongly associated with protection from clinical symptoms of malaria and exponential parasite multiplication, while the gold standard GIA was not. The breadth of Fc-mediated effector function discriminated clinical immunity following the challenge. These findings present a shift in the understanding of the mechanisms that underpin immunity to malaria and have important implications for vaccine development.
AU  - Nkumama,IN
AU  - Ogwang,R
AU  - Odera,D
AU  - Musasia,F
AU  - Mwai,K
AU  - Nyamako,L
AU  - Murungi,L
AU  - Tuju,J
AU  - Fürle,K
AU  - Rosenkranz,M
AU  - Kimathi,R
AU  - Njuguna,P
AU  - Hamaluba,M
AU  - Kapulu,MC
AU  - Frank,R
AU  - CHMI-SIKA,study team
AU  - Osier,FHA
DO  - 10.1016/j.immuni.2024.05.001
EP  - 1224
PY  - 2024///
SP  - 1215
TI  - Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.
T2  - Immunity
UR  - http://dx.doi.org/10.1016/j.immuni.2024.05.001
UR  - https://www.ncbi.nlm.nih.gov/pubmed/38788711
VL  - 57
ER  - 

Download